Co-transplantation of Human Mesenchymal Stem Cells Promotes Human CD34+ Cells Engraftment in a Dose-dependent Fashion in NOD/SCID Mice by Park, Seong-Kyu et al.
INTRODUCTION
In addition to hematopoietic stem cells (HSCs), the bone
marrow contains a second type of stem cells that are capable of
giving rise to multiple mesenchymal cell lineages, namely,
mesenchymal stem cells (MSCs) (1, 2). Bone marrow stromal
cells have been shown to include MSCs, which are thought
to support hematopoiesis by creating an optimal microenvi-
ronment (the marrow matrix), and by providing cytokines
and other regulatory factors that stimulate and enhance pro-
liferation of the hematopoietic elements (3). Moreover, mul-
tipotent human MSCs can be isolated from bone marrow and
expanded more than 1-billion-fold in cell culture without
loss of stem cell capacity (4). These cells are capable of differ-
entiating into osteoblasts, adipocytes, chondrocytes, myocytes,
neural elements, and stromal fibroblasts under defined in vitro
or in vivo conditions, and show an identical phenotype when
grown from a single cell clone (5-7). In the area of hemato-
poiesis, MSCs are being used clinically to support hematopoi-
etic recovery by replacing stroma. Moreover, a growing body
of clinical evidence suggests the existence of a link between
the efficiency of hematopoietic recovery and the degree of
stromal damage that occurs as a result of myeloablative can-
cer therapy (8). As a result, therapy-ablated marrow may not
be able to sustain hematopoietic stem cell maintenance or
their differentiation into specific lineages, such as, megakary-
ocytes and platelets. In addition, a prolonged stromal defect
in growth factor production, like early-stage cytokines, such
as, interleukin-6, leukemia inhibitory factor, stem cell factor
and granulocyte-colony stimulating factor, after autologous
bone marrow transplantation has been observed for as long
as a year in patients with hematologic disorders (9).
Independent laboratories have shown that recipients of un-
manipulated allogeneic bone marrow transplants have only
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Co-transplantation of Human Mesenchymal Stem Cells Promotes
Human CD34+ Cells Engraftment in a Dose-dependent Fashion in
NOD/SCID Mice
Mesenchymal stem cells (MSCs) have recently been identified and characterized
in humans. Moreover, MSC secrete cytokines that can support hematopoietic pro-
genitor growth. In the present study, we evaluated whether the efficacy of hemato-
poietic stem cell transplantation is improved by their co-transplantation with MSC,
and whether this is positively correlated with the dose of infused MSCs. Accordingly,
irradiated NOD/SCID mice were transplanted with 1× ×10
5 human CD34+ cells in
the presence or absence of culture expanded MSCs (1× ×10
6 or 5× ×10
6). We eval-
uated human hematopoietic cell engraftment by flow cytometry and assessed MSC
tissue distributions by fluorescence in situ hybridization. We found that CD45+ and
CD34+ cell levels were significantly elevated in a dose-dependent manner in co-
transplanted mice 4 weeks after transplantation. The engraftments of CD33+ and
CD19+ cells also increased dose-dependently. However, the engraftment of CD3+
cells did not increase after co-transplantation with MSCs. Human Y chromosome+
cells were observed in multiple tissues and were more frequently observed in mice
co-transplanted with 5× ×10
6 rather than 1× ×10
6 MSCs. These results suggest that
MSCs are capable of enhancing hematopoietic cell engraftment and distribution in
multiple organs in a dose-dependent fashion.
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host-type marrow stromal cells and MSCs in bone marrow
(10, 11). These results are attributed to the inability of the
conditioning regimen to ablate host marrow stroma and/or
the inability of stromal progenitors of donor origin to engraft.
In addition, the number of MSCs has been estimated to be
low in an average bone marrow graft (400-1,000 MSCs/kg).
On the other hand, a recent report noted that allogeneic osteo-
blasts could be detected in recipients with osteogenesis imper-
fecta (OI) after sibling-matched allogeneic bone marrow trans-
plantation (12). These findings suggest that osteoblasts may
be transplanted successfully under certain conditions. Stro-
mal chimerism has been achieved using infusions of culture-
expanded stromal progenitors in murine models, and xeno-
transplantation models have been developed to determine
the homing of human MSCs in animals. Human MSCs were
detected predominantly in bone marrow, and less frequently
in other organs of immunodeficient NOD/SCID mice 8 weeks
after infusion. Moreover, recent data indicate that MSC co-
infusion enhances human hematopoiesis in NOD/SCID mice
(13, 14). Based on encouraging data obtained in both rodent
and large animal models, clinical studies of MSC transplan-
tation are underway in both autologous and allogeneic set-
tings. Koc et al. (15) found that the co-infusion of autologous
MSCs together with autologous HSCs is free of toxicity and
that it is associated with rapid hematopoietic recovery in 28
women receiving high dose chemotherapy for advanced breast
carcinoma. In this report, we demonstrate that co-transplan-
tation with human MSCs can enhance the engraftment of
human hematopoietic stem cells in NOD/SCID mice, and
that this engraftment-enhancing effect increases according
to the number of infused MSCs. We also show that an increased
dose of MSCs enhances the tissue distribution of human MSCs
in multiple tissues in NOD/SCID mice. Our results show
that MSCs are capable of enhancing hematopoietic engraft-
ment and distribution to multiple organs in a dose-depen-
dent fashion.
MATERIALS AND METHODS
Collection and isolation of CD34+ + cells from umbilical
cord blood (UCB)
UCB was obtained at the time of full-term deliveries, after
receiving informed consent for the study protocol by our hos-
pital’s ethics committee. UCB was collected after clamping
and cutting of cords by draining blood into sterile collection
tubes containing the anticoagulant citrate-phosphate dextrose.
Mononuclear cells (MNCs) were isolated from UCB using
Ficoll-Hypaque (1.077 g/cm3, Sigma, St Louis, MO) densi-
ty centrifugation (400 g for 25 min). CD34+ cells were iso-
lated using a magnetic cell sorting system, Mini-MACS (Mil-
tenyi Biotec, Auburn, CA), according to the manufacturer’s
instructions. Purity was determined by flow cytometry using
a FITC-conjugated anti-CD34 (anti-HPCA-2, Becton-Dick-
inson, Mountain View, CA), and was found to be 90 to 95%.
Human MSCs isolation and ex vivo culture
Ten to twenty mililiters of bone marrow aspirate was ob-
tained under sterile conditions by posterior iliac crest punc-
ture from bone marrow transplantation donors with given
informed consent. Human MSCs were isolated and culture-
expanded according to the method described by Pittenger
et al. (1). MNCs were isolated from bone marrow, and cells
were cultured in human MSC medium composed of Dulbec-
co’s modified Eagle’s low glucose medium (DMEM-LG; Gib-
coBRL, Grand Island, NY) containing 10% fetal bovine
serum (FBS; GibcoBRL) and 1% antibiotic-antimycotic
solution (GibcoBRL). Human MSCs were confirmed to be
negative for hematopoietic markers by flow cytometry and
to be capable of differentiating into osteocytes, chondrocytes,
and adipocytes in vitro (Fig. 1, 2).
Differentiation of MSCs
MSCs were induced to differentiate into adipocytes by treat-
ing confluent second passage monolayer cultures with 1  M
dexamethasone (Sigma, St. Louis, U.S.A.), 0.5 mM methyl-
isobutylxanthine (Sigma), 10  g/mL insulin (Sigma), and
100 mM indomethacin (Sigma) in DMEM containing 10%
FBS. Adipogenic differentiation was demonstrated by the
accumulation of lipid vesicles stained red by Oil red O (Sig-
ma). The osteogenic differentiation of MSCs was induced by
culturing confluent monolayers in DMEM containing 10%
FBS, 0.1  M dexamethasone, 50  M ascorbate (Sigma), and
10  M  -glycerol- phosphate (Sigma). MSC osteogenic dif-
ferentiation over 21 days was demonstrated by increases in
alkaline phosphatase and calcium accumulation. Alkaline
phosphatase was detected histologically, and calcium was
stained by the Kossa’s method. The chondrogenic differen-
tiation of MSCs was in- duced by pellet culture in 500  L
of DMEM containing 10% FBS, 0.1  M dexamethasone,
50  M ascorbic acid 2-phosphate (Sigma), and 1  g/mL trans-
forming growth factor- ( TGF- R&D System, Minnea-
polis, MN). Under low speed centrifugation (1,000 g for 5
min), a dense mass of cells formed at the bottom of conical
centrifuge tubes. Chondrogenic differentiation was demon-
strated by toluidine blue staining after 3 weeks of culture.
Mice
Female NOD/SCID mice (5-6 weeks old), purchased from
Charles-River Laboratory (Tokyo), were housed in micro-iso-
lator cages on laminar flow racks at the animal facilities of
the Catholic University of Korea. Mice were provided a ster-
ile diet and autoclaved acidified water.414 S.-K. Park, J.-H. Won, H.-J. Kim, et al.
Xenotransplantation of human cord blood CD34+ + cells
and MSCs into mice
NOD/SCID mice were sublethally irradiated (3.5 Gy) 4
to 6 hr before transplantation. Human female cord blood
CD34+cells were injected at a final volume of 100  L Iscove’s
Modified Dulbecco’s Media (IMDM; GibcoBRL) per mouse
and human male MSCs were injected with IMDM at a vol-
ume of 100 L/106 MSCs per mouse. Both CD34+ cells and
MSCs were injected via a tail vein. Two mice were assigned
to each experimental group. In three separate experiments,
mice were assigned to receive 1×105 CD34+cells, CD34+
cells plus 1×106 MSCs, or CD34+ cells plus 5×106 MSCs.
One mouse treated with 5×106 MSCs in the first experiment
died after MSCs infusion due to myocardial infarction (patho-
logically confirmed, data not shown).
Detection of human hematopoietic cells in NOD/SCID
mice by flow cytometry
Four weeks after transplantation, mice were sacrificed by
carbon dioxide inhalation, and bone marrow (BM) cells were
collected by flushing both femurs with RPMI medium (Gibco
BRL). Cell suspensions were stained with mouse anti-human
monoclonal antibodies, fluorescein isothiocyanate (FITC)-
conjugated CD45 antibody and phycoerythrin (PE)-conju-
gated CD34, CD13, CD33, CD3, and CD19 antibodies (Bec-
ton-Dickinson, Mountain View, CA). Flow cytometry to detect
human CD45+ and CD34+, CD13+, CD33+, CD3+, or
CD19+ cells was performed on a FACScan flow cytometer
(Becton-Dickinson). FITC- and PE-conjugated mouse iso-
type control antibodies were used for each culture, and 5,000-
Osteoblasts
Mesenchymal stem cells
Chondrocytes Adipocytes
Fig. 2. Culture-expanded human mesenchymal stem cells exhib-
ited a fibroblastic morphology (top panel). Under specific differ-
entiation-inducing conditions, mesenchymal stem cells differenti-
ated into osteoblasts, chondrocytes, and adipocytes.
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Fig. 1. Immunophenotype of cultured human mesenchymal stem cells. Mesenchymal stem cells expressed CD105 and CD166, but were
negative for CD34, CD45, and CD14.
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10,000 events were counted for each analysis. Differences in
engraftment percentages were calculated using the Student’s
t-test. p values of <0.05 were considered statistically signifi-
cant.
Detection of human MSCs in NOD/SCID mice by 
fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) for the human Y
chromosome was used to detect transplanted MSCs in BM,
spleen, liver, lung, kidney, heart, skeletal muscle, intestine,
and skin of NOD/SCID mice at four weeks after transplan-
tation in the second and third experiments. Total numbers
of Y chromosome positive cells in ten×high-power fields
were counted.
RESULTS
Differential potential of MSCs
Culture of bone marrow MNCs produced a monomorphic
confluent adherent layer of elongated fibroblast-like cells that
survived multiple passages under mesenchymal culture condi-
tions. At the end of the second passage, bone marrow derived
MSCs had successfully differentiated along osteogenic, chon-
drogenic, and adipogenic lineages, using methods described
above (Fig. 2).
Effect of MSCs on human hematopoietic cell engraftment
in NOD/SCID mice
Transplantation of UCB CD34+ cells (1×105/mouse) in
the presence of MSCs (1×106 and 5×106/mouse) resulted
in significantly higher engraftment levels in the BM of NOD/
SCID mice than was observed after transplanting UCB CD34+
cells alone. The mean percentage of CD45+ cells in the BM
of NOD/SCID mice according to the MSCs number, i.e., 1×
106 or 5×106, increased to 41.05±5.62 and 55.58±8.26,
respectively, compared with 29.18±1.00 for transplantation
with CD34+ cells without MSCs (p<0.05). The difference
between the group infused with 1×106 MSCs and the group
infused with 5×106 MSCs was statistically significant (p<
0.05) (Fig. 3). The mean percentage of CD45+-CD34+ cells
increased to 13.78±1.50 and 17.43±2.05 at these MSC
dosages, compared with 7.76±0.37 for transplantation with
CD34+ cells without MSCs (p<0.05). In addition, the groups
infused with 1×106 or 5×106 were significantly different
(p<0.05) (Fig. 3).
Effects of MSCs on human myeloid cell engraftment in
NOD/SCID mice
Co-transplantation of MSCs significantly increased the level
of human myeloid cell engraftment in NOD/SCID mouse
BM. The mean percentage of CD45+-CD33+ cells in NOD/
SCID mouse BM at MSC doses of 1×106 and 5×106 were
19.62±1.18 and 24.38±3.05, respectively, compared with
6.54±0.17 for transplantation with CD34+ cells alone (p<
0.05). Moreover, the level of myeloid cell engraftment in the
group infused with a high dose of MSCs was significant higher
than in the group infused with a lower dose (p<0.05) (Fig. 3).
Mean percentages of CD45+-CD13+ cells increased to 21.64±
2.04 and 24.45±3.41 for high and low MSC doses, compared
with 10.34±0.57 for transplantation with CD34+ cells
alone (Fig. 3). Although there was a distinct difference bet-
ween the group co-transplanted with MSCs and the group
transplanted with HSC alone (p<0.05), we did not notice a
difference between levels of HSC engraftment according to
the number of MSCs co-transplanted.
Effects of MSCs on human lymphoid cell engraftment in
NOD/SCID mice
The mean percentages of CD45+-CD19+ cells in NOD/
SCID mouse BM according to the MSC dose were signifi-
cantly increased to 9.93±4.77 and 24.39±11.22, respec-
tively, compared with 7.08±1.46 of CD34+cells alone (p<
0.05). Co-transplantation of MSCs at 5×106 significantly
increased the level of human B lymphoid cell engraftment
in NOD/SCID mouse BM (p<0.05). Mean percentages of
CD45+-CD3+ cells engrafted by low and high MSC doses
were 2.89±1.90 and 4.43±1.64, respectively, compared
CD34+
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Fig. 3. Effects of MSCs on human UCB 34+ cell engraftment in
NOD/SCID mice. Co-transplantation with UCB CD34+ cells and
MSCs resulted in higher engraftment levels in NOD/SCID mouse
bone marrow 4 weeks after transplantation than after transplan-
tation with UCB CD34+ cells alone. Moreover, this engraftment-
promoting effect was related to the MSC dosage and increased
myeloid and B lymphoid cell numbers but not those of T-lymphoid
cells. *A significant difference (p<0.05) between the cotransplant-
ed group and the group transplanted with CD34+ alone. 
� Signifi-
cant (p<0.05) between the group infused with 1×10
6 MSCs and
the group infused with 5×10
6 MSCs.
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with 3.02±1.17 for CD34+ cells alone. Co-transplantation
of MSCs did not increase the level of human T lymphoid cell
engraftment in NOD/SCID mouse BM (Fig. 3).
Engraftment of human MSCs in NOD/SCID mice
Human Y chromosome positive cells were found in BM,
Fig. 4. Human X chromosome (green) and Y chromosome (red) expression by fluorescence in situ hybridization (FISH) analysis. Human
X and Y chromosomes were detected in bone marrow, spleen, liver, lung, and kidney. Y chromosomes were detected in the heart, intes-
tine, and skin (results of heart and intestine are not shown).
Bone marrow X(+), Y(+) Spleen- X(+) & Y(+)
Liver- X(+) & Y(+) Lung- X(+) & Y(+)
Kidney- X(+) & Y(+) Skin- Y(+)Co-transplantation of Human MSCs into NOD/SCID Mice 417
spleen, liver, lung, kidney, heart, intestine, and skin of NOD/
SCID mice at four weeks after transplantation but not in
skeletal muscle. The distribution of human Y chromosome
positive cells differed by tissue; Y chromosome positive cells
were found more frequently in the liver, lung, and kidney
than in other tissues (Fig. 4, Table 1). In addition, numbers
of these cells were higher in mice that received a higher dose
of MSCs in same tissues.
DISCUSSION
We infused relatively low doses of CD34+ cells (1×105
cells) into NOD/SCID mice in this study. We tried to evalu-
ate the dose-dependent effect of MSCs on HSC engraftment,
and thus, we used relatively high doses of MSCs (5×106/ani-
mal) as compared with the doses (1×106/animal) usually
applied. We observed that the high-dose MSC group showed
significantly higher levels of HSC engraftment than the low-
dose (1×106/animal) MSC group, thus confirming that MSCs
have a dose-dependent effect on HSC engraftment.
Noort et al. (13) demonstrated in NOD/SCID mice that
engraftment levels were higher in the co-transplantation of
MSCs (1×106) and UCB CD34+ cells than in transplanta-
tion with UCB CD34+ cells alone. They also demonstrated
that the effects of MSC co-transplantation on BM engraft-
ment were more pronounced after transplantation with rela-
tively low doses of CD34+ cells (0.03-0.1×106). The eng-
raftment level increased three- to four-fold with MSCs co-
transplantation with low doses of UCB CD34+ cells. How-
ever, no further additive effect was observed at higher doses
of UCB CD34+ cells. Angelopoulos et al. (14) reported that
MSC co-transplantation enhanced human cell engraftment
when CD34+ cell infusion was limited, and that the effica-
cy of engraftment was blunted when the CD34+ cell dose
was increased to 1.5×106. These data suggested that MSC
co-transplantation can enhance the efficacy of engraftment
if only a low dose of CD34+ cells is available. We observed
similar effects in the present study.
Few reports have evaluated whether the engraftment-en-
hancing effect of MSCs is related to the MSC dose, which is
why we decided to use a higher dose in this study. However,
problems occur when animal models are administered higher
doses. Initially, we wondered whether higher doses increase
the risk of lethal vascular complications, such as, pulmonary
embolism. In fact, the frequency of sudden death within 24
hr after MSC infusion did tend to increase slightly, but this
was not significant (not shown data). Additionally, the use of
a high cell dose could be criticized for not being clinically
relevant. However, the objective of this study was to deter-
mine the effect that MSCs have on HSC engraftment, and
therefore we chose a somewhat extreme model.
The effect of MSCs on HSC engraftment is not lineage-res-
tricted, with grafts being comprised B lymphoid cells as well
as myeloid cells. However, T lymphoid cell levels were not
increased by co-transplanting HSCs with MSCs. This sup-
portive activity may have been derived from the specific char-
acteristics of MSCs, which have a suppressive effect on the
proliferation of T lymphocytes and a modulating effect on
the immune system (16, 17). However, no mechanism exp-
laining the immunoregulatory effects of MSCs has been elu-
cidated (16-20). 
Several studies in animal models have demonstrated that
stromal cells not only seed the bone marrow but also enhance
hematopoietic recovery (13, 21, 22). However, the transplan-
tation ability of bone marrow stromal elements still remains
an open issue in humans (23). Several independent clinical
studies have shown that recipients transplanted with unma-
nipulated allogeneic bone marrow have only host-type mar-
row stromal cells and MSCs in bone marrow (11, 24). This
finding suggests that neither stromal progenitors nor MSCs
are able to engraft into bone marrow because a ‘‘normal’’ bone
marrow graft contains too few MSCs to support engraftment.
However, others have reported contrary results (25, 26). This
discordance may originate from either methodological differ-
ences concerning the detection of donor-derived mesenchy-
mal cells, or from differences between doses of reinfused stro-
mal cells. To detect engrafted donor derived cells in various
tissue types, green fluorescence protein (GFP) is most widely
used as a reporter. However, even though the GFP method
has a higher sensitivity than the monoclonal antibody method
for membrane antigen, it is difficult to determine whether
GFP expressing cells are quiescent. Therefore, we decided to
use FISH for the human X and Y chromosomes to detect
engrafted donor derived cells in the organs of NOD/SCID
mice. The data obtained provide evidence that human HSCs
can be engrafted into various organs in NOD/SCID mice,
and that the number of engrafted cells increases in propor-
tion to the number of MSCs infused.
Our results reveal that MSCs have an accelerating effect
FISH, fluorescence in situ hybridization; MSCs, mesenchymal stem cells;
NF, not found.
CD34+ cells (1×10
5)+
MSCs (1×10
6)
1234
CD34+ cells (1×10
5)+
MSCs (5×10
6)
1234
Heart NF 1 NF 2 NF 1 NF NF
Lung NF NF >5 NF 1 >5 2 4
Kidney NF NF 4 2 >5 NF >5 2
Liver NF NF >5 NF > 5 >5 >5 >5
Spleen NF NF >5 NF 1 1 1 NF
Intestine NF NF NF NF 1 >5 NF 4
Muscle NF NF NF NF NF NF NF NF
Skin NF NF NF NF 1 NF NF NF
Table 1. Results obtained by FISH for human Y chromosome
four weeks after cotransplanting human CD34+ cells and MSCs
in various organs of NOD/SCID mice (number of Y chromosome
positive cells)418 S.-K. Park, J.-H. Won, H.-J. Kim, et al.
on HSC engraftment and that this is dose-dependent. It is
also suggested that a graft engineered to increase the num-
ber of MSCs may pave the way for further applications in the
field of transplantation with respect to hematopoietic support
and efficient engraftment.
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